可溶性ST2在射血分数保留的心力衰竭患者中的表达及其预后价值

被引:18
作者
张丽
丁世芳
蒋桔泉
陈志楠
卢青
付文波
彭毅
机构
[1] 南方医科大学附属广州军区武汉总医院心内科
关键词
心力衰竭; 可溶性ST2; 氨基末端脑钠肽前体; 左室射血分数; 心血管事件;
D O I
10.13201/j.issn.1001-1439.2016.05.014
中图分类号
R541.6 [血液循环衰竭];
学科分类号
100201 [内科学];
摘要
目的:比较射血分数保留的心力衰竭(HFPEF)患者和射血分数下降的心力衰竭(HFREF)患者治疗过程中血浆可溶性ST2(sST2)及氨基末端脑钠肽前体(NT-proBNP)的水平和早期变化,并探讨其对心血管事件的预测价值。方法:将61例急性失代偿性心衰患者按照左室射血分数(LVEF)分为HFPEF组(35例)及HFREF组(26例)。比较两组入院时、入院第7天sST2及NT-proBNP的水平,随访并记录患者入院后6个月心血管事件(全因死亡、心衰再住院)的发生情况。结果:HFREF组患者入院时、入院第7天sST2、NT-proBNP水平高于HFPEF组(均P<0.05)。两组入院第7天NT-proBNP水平较入院时明显下降,而sST2在治疗过程中变化不明显。经Logsitic回归分析发现(纳入因素包括NT-proBNP),入院时sST2水平是上述两种心衰患者发生心血管事件的独立危险因素(HFPEF组:OR:1.411,95%CI:1.038~1.918,P<0.05;HFREF组:OR:1.033,95%CI:1.009~1.058,P<0.001)。通过ROC曲线发现,只有NT-proBNP的变化值具有预测心血管事件的价值(ROC曲线下面积为0.753,界值为2 852pg/ml,灵敏度92.3%,特异度56.2%,P=0.005)。而治疗过程中sST2水平的短期变化值无预测心血管事件的价值。结论:HFPEF患者血浆sST2水平显著低于HFREF患者。入院时sST2水平是急性心衰患者发生心血管事件的独立危险因素,与LVEF无关。NT-proBNP水平的短期变化具有预测心血管事件的价值。
引用
收藏
页码:487 / 491
页数:5
相关论文
共 10 条
[1]
不同类型心力衰竭患者血尿酸与NT-proBNP、hs-CRP的关系 [J].
曹丹丹 ;
张菲斐 ;
韩战营 ;
邱春光 ;
黄振文 .
临床心血管病杂志, 2013, 29 (06) :417-419
[2]
Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction [J].
Wijk, Sandra Sanders-van ;
van Empel, Vanessa ;
Davarzani, Nasser ;
Maeder, Micha T. ;
Handschin, Rolf ;
Pfisterer, Matthias E. ;
Hans-Peter Brunner-La Rocca .
EUROPEAN JOURNAL OF HEART FAILURE, 2015, 17 (10) :1006-1014
[3]
Elevated serum soluble ST2 levels may predict the fatal outcomes in patients with chronic heart failure.[J].Heng-Chen Yao;Xiao-Yun Li;Qian-Feng Han;Lan-Hua Wang;Tao Liu;Yan-Hong Zhou;Mei Zhang;Le-Xin Wang.International Journal of Cardiology.2015,
[4]
A Novel Paradigm for Heart Failure With Preserved Ejection Fraction.[J].Walter J. Paulus;Carsten Tsch?pe.Journal of the American College of Cardiology.2013, 4
[5]
Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma — The Presage? ST2 assay.[J].Benjamin Dieplinger;James L. Januzzi;Martin Steinmair;Christian Gabriel;Werner Poelz;Meinhard Haltmayer;Thomas Mueller.Clinica Chimica Acta.2009, 1
[6]
Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients With Acute Heart Failure [J].
Rehman, Shafiq U. ;
Mueller, Thomas ;
Januzzi, James L., Jr. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 52 (18) :1458-1465
[7]
Measurement of the interleukin family member ST2 in patients with acute dyspnea [J].
Januzzi, James L., Jr. ;
Peacock, W. Frank ;
Maisel, Alan S. ;
Chae, Claudia U. ;
Jesse, Robert L. ;
Baggish, Aaron L. ;
O'Donoghue, Michelle ;
Sakhuja, Rahul ;
Chen, Annabel A. ;
van Kimmenade, Roland R. J. ;
Lewandrowski, Kent B. ;
Lloyd-Jones, Donald M. ;
Wu, Alan H. B. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (07) :607-613
[8]
ST2 suppresses IL-6 production via the inhibition of IκB degradation induced by the LPS signal in THP-1 cells [J].
Takezako, N ;
Hayakawa, M ;
Hayakawa, H ;
Aoki, S ;
Yanagisawa, K ;
Endo, H ;
Tominaga, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 341 (02) :425-432
[9]
Identification of serum soluble ST2 receptor as a novel heart failure biomarker [J].
Weinberg, EO ;
Shimpo, M ;
Hurwitz, S ;
Tominaga, S ;
Rouleau, JL ;
Lee, RT .
CIRCULATION, 2003, 107 (05) :721-726
[10]
Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction [J].
Weinberg, EO ;
Shimpo, M ;
De Keulenaer, GW ;
MacGillivray, C ;
Tominaga, S ;
Solomon, SD ;
Rouleau, JL ;
Lee, RT .
CIRCULATION, 2002, 106 (23) :2961-2966